SpringWorks Therapeutics Inc (SWTX)
44.86
+0.09
(+0.20%)
USD |
NASDAQ |
May 17, 16:00
44.86
0.00 (0.00%)
After-Hours: 20:00
SpringWorks Therapeutics Cash from Financing (Quarterly): -0.552M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -0.552M |
| December 31, 2023 | 299.07M |
| September 30, 2023 | -0.242M |
| June 30, 2023 | -0.342M |
| March 31, 2023 | -1.848M |
| December 31, 2022 | 0.298M |
| September 30, 2022 | 340.23M |
| June 30, 2022 | -0.088M |
| March 31, 2022 | 0.261M |
| December 31, 2021 | 0.244M |
| September 30, 2021 | 0.425M |
| Date | Value |
|---|---|
| June 30, 2021 | 0.129M |
| March 31, 2021 | 0.359M |
| December 31, 2020 | 269.97M |
| September 30, 2020 | 0.428M |
| June 30, 2020 | 0.078M |
| March 31, 2020 | 0.006M |
| December 31, 2019 | 0.02M |
| September 30, 2019 | 169.73M |
| June 30, 2019 | 0.00 |
| March 31, 2019 | 163.96M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-1.848M
Minimum
Mar 2023
340.23M
Maximum
Sep 2022
53.91M
Average
0.1865M
Median
Cash from Financing (Quarterly) Benchmarks
| Geron Corp | 147.80M |
| Verastem Inc | 0.846M |
| Karyopharm Therapeutics Inc | -- |
| Syndax Pharmaceuticals Inc | 2.168M |
| Arvinas Inc | 1.60M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -78.93M |
| Cash from Investing (Quarterly) | 21.46M |
| Free Cash Flow | -244.89M |
| Free Cash Flow Per Share (Quarterly) | -1.078 |
| Free Cash Flow to Equity (Quarterly) | -79.51M |
| Free Cash Flow Yield | -8.27% |